Volume 44, Issue 2, Pages (February 2006)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Volume 50, Issue 4, Pages (April 2009)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Volume 67, Issue 2, Pages (August 2017)
Volume 68, Issue 5, Pages (May 2018)
Volume 42, Issue 6, Pages (June 2005)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation.
Volume 44, Issue 4, Pages (April 2006)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Virological tools to diagnose and monitor hepatitis C virus infection
Living donor liver transplantation: is the hype over?
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Volume 50, Issue 4, Pages (April 2009)
Volume 133, Issue 5, Pages (November 2007)
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C  Chi–Jen Chu, Munira Hussain,
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency  Danny Ka-Ho Wong, Wai-Kay.
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 133, Issue 5, Pages (November 2007)
Volume 130, Issue 7, Pages (June 2006)
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection  Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence.
From non-A, non-B hepatitis to hepatitis C virus cure
Volume 42, Issue 2, Pages (February 2005)
Chronic Hepatitis B: Current Testing Strategies
Volume 44, Issue 1, Pages (January 2006)
‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?  Andres Duarte-Rojo, Elizabeth Jenny Heathcote,
Management of cirrhosis due to chronic hepatitis C
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice1   Thomas.
Volume 62, Issue 1, Pages (January 2015)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Economics of chronic hepatitis B and hepatitis C
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients  Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon.
Volume 65, Issue 2, Pages (August 2016)
Volume 59, Issue 4, Pages (October 2013)
Volume 50, Issue 4, Pages (April 2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Volume 50, Issue 3, Pages (March 2009)
Immigration and viral hepatitis
Outcomes of Patients With Hepatitis B Who Developed Antiviral Resistance While on the Liver Transplant Waiting List  Melissa K. Osborn, Steven H. Han,
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Chronic hepatitis B in children and adolescents
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Genetics of hepatocellular carcinoma: The next generation
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Emmet B. Keeffe, Douglas T
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 44, Issue 2, Pages 283-290 (February 2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B  Scott K. Fung, Hee Bok Chae, Robert J. Fontana, Hari Conjeevaram, Jorge Marrero, Kelly Oberhelman, Munira Hussain, Anna S.F. Lok  Journal of Hepatology  Volume 44, Issue 2, Pages 283-290 (February 2006) DOI: 10.1016/j.jhep.2005.10.018 Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Virologic response to adefovir. Percent of patients with reduction in HBV DNA by <3 log10, 3.1–5 log10 and >5 log10copies/ml at month 6 (shaded bars) and at month 12 (open bars) is illustrated. Journal of Hepatology 2006 44, 283-290DOI: (10.1016/j.jhep.2005.10.018) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Virologic response according to initial virologic response. Patients who achieved an initial virologic response are represented by the solid line; patients who did not have an initial virologic response are represented by the dashed line. Journal of Hepatology 2006 44, 283-290DOI: (10.1016/j.jhep.2005.10.018) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Cumulative probability of adefovir resistance. The cumulative probability of adefovir resistance at months 6, 12, 18 and 24 is 0, 0, 16 and 22%, respectively. The number of patients at risk at each time point is indicated. [This figure appears in colour on the web.] Journal of Hepatology 2006 44, 283-290DOI: (10.1016/j.jhep.2005.10.018) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Clinical course of a patient with adefovir resistance. The clinical course and response to salvage therapy for a representative patient with adefovir resistance is depicted. Antiviral treatment is indicated above the graph: lamivudine was given for >1 year previously (data not shown), adefovir was given for 21 months and entecavir therapy is ongoing. HBV polymerase gene mutations are represented in the boxed panel. The solid line represents HBV DNA levels and the dashed line ALT levels. This patient was described in a previous case series, with follow-up on entecavir of only 8 months [14]. LAM, lamivudine; ADV, adefovir; ETV, entecavir; rt, reverse transcriptase; PCR, polymerase chain reaction. Journal of Hepatology 2006 44, 283-290DOI: (10.1016/j.jhep.2005.10.018) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions